Avior Wealth Management LLC lowered its position in Masimo Co. (NASDAQ:MASI - Free Report) by 42.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,279 shares of the medical equipment provider's stock after selling 2,452 shares during the quarter. Avior Wealth Management LLC's holdings in Masimo were worth $542,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently modified their holdings of the company. NBC Securities Inc. lifted its stake in shares of Masimo by 47.1% during the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 73 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 123 shares in the last quarter. Trust Co. of Vermont acquired a new position in Masimo in the fourth quarter worth about $33,000. Northwestern Mutual Wealth Management Co. increased its holdings in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 200 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Masimo by 136.5% during the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider's stock valued at $77,000 after buying an additional 269 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have recently weighed in on MASI. Piper Sandler boosted their price target on Masimo from $180.00 to $210.00 and gave the company an "overweight" rating in a report on Wednesday, December 18th. Stifel Nicolaus reissued a "buy" rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. BTIG Research lifted their price target on shares of Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a report on Monday, October 14th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday. Finally, Raymond James lifted their target price on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $179.67.
Get Our Latest Research Report on Masimo
Masimo Stock Performance
Masimo stock traded up $2.16 during midday trading on Friday, reaching $170.24. 337,899 shares of the stock traded hands, compared to its average volume of 419,156. The firm has a fifty day moving average price of $170.32 and a two-hundred day moving average price of $142.65. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The firm has a market cap of $9.11 billion, a price-to-earnings ratio of 117.41 and a beta of 1.01. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.
Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same period in the prior year, the company posted $0.63 EPS. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. On average, equities research analysts forecast that Masimo Co. will post 4.1 earnings per share for the current year.
Masimo Company Profile
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Recommended Stories
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.